Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 8/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6896112 | 0.92 | PARP1 (0.40) | HTR6PARP1CNR2 | |
| SCHEMBL6895417 | 0.86 | CNR2 (0.43) | HTR6PARP1CNR2 | |
| SCHEMBL419017 | 0.81 | JAK2 (0.43) | PARP1CNR2PAX8 | |
| SCHEMBL6896271 | 0.79 | PARP1 (0.37) | PARP1CNR2PAX8 | |
| SCHEMBL6893814 | 0.78 | PARP1 (0.38) | PARP1CNR2 | |
| SCHEMBL10010656 | 0.77 | CNR2 (0.36) | PARP1CNR2 | |
| SCHEMBL27869259 | 0.73 | NPY1R (0.41) | CNR2 | |
| SCHEMBL6894057 | 0.73 | PARP1 (0.39) | PARP1CNR2 | |
| SCHEMBL422578 | 0.73 | PARP1 (0.39) | PARP1PAX8 | |
| SCHEMBL420597 | 0.73 | GNRHR (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172350-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20110065694-A1 | Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2011-03-17 | — | — | US | disclosed |
| WO-2011031818-A2 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031816-A2 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065694-A1 | Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof | HRH3, HRH4, HRH2 | HTR6 107/4885PARP1 4099/4885CNR2 128/4885 |
| US-20120172350-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | HTR6 107/4885PARP1 4099/4885CNR2 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.